Other treatment-related grade @-@ adverse events include generalised oedema and myalgia ( each in two -LSB- @ % -RSB- patients ) in those given pembrolizumab @ mg/kg ; hypopituitarism , colitis , diarrhoea , decreased appetite , hyponatremia , and pneumonitis ( each in two -LSB- @ % -RSB- ) in those given pembrolizumab @ mg/kg ; and anaemia ( nine -LSB- @ % -RSB- ) , fatigue ( eight -LSB- @ % -RSB- ) , neutropenia ( six -LSB- @ % -RSB- ) , and leucopenia ( six -LSB- @ % -RSB- ) in those assigned to chemotherapy .